Procarta's

snare™

antibacterials consist of two proprietary inventions:

• An oligonucleotide therapeutic (TFD) that blocks expression of targeted, essential bacterial genes to kill drug-resistant bacterial pathogens
• A bacterial-specific delivery system for TFDs into Gram-positive (MRSA) and Gram-negative (P. aeruginosa) pathogens

Procarta has created a proprietary platform able to rapidly, efficiently and systematically identify TFD sequences to counter a broad range of bacterial infections. This represents a novel paradigm for antibacterial discovery and the company has moved to gain IP protection around this novel class of first-line therapeutics.

As such the key advantages of

snare™

antibacterials are:

• Designed to treat difficult infections

• Adaptable technology to address emerging antibacterial indications

• Strong IP position